ChromaDex (CDXC) Downgraded by ValuEngine

ValuEngine lowered shares of ChromaDex (NASDAQ:CDXC) from a hold rating to a sell rating in a research report released on Friday.

Several other analysts have also weighed in on the stock. Zacks Investment Research lowered shares of ChromaDex from a buy rating to a hold rating in a research note on Wednesday, November 29th. HC Wainwright lifted their price target on shares of ChromaDex from $6.00 to $8.00 and gave the company a buy rating in a research report on Monday, November 27th. Finally, Ladenburg Thalmann Financial Services initiated coverage on shares of ChromaDex in a research report on Monday, September 25th. They issued a buy rating and a $7.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. ChromaDex currently has an average rating of Hold and a consensus price target of $7.13.

ChromaDex (NASDAQ CDXC) traded down $0.33 during trading hours on Friday, hitting $6.59. 660,100 shares of the stock traded hands, compared to its average volume of 312,212. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 4.12. ChromaDex has a 12 month low of $2.25 and a 12 month high of $7.24.

In other ChromaDex news, major shareholder River Ventures Ltd Champion purchased 731,707 shares of ChromaDex stock in a transaction that occurred on Friday, November 17th. The stock was acquired at an average price of $4.10 per share, with a total value of $2,999,998.70. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 11.59% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of CDXC. Bank of Montreal Can purchased a new position in ChromaDex during the 2nd quarter worth $168,000. LMR Partners LLP purchased a new position in ChromaDex during the 2nd quarter worth $347,000. Goldman Sachs Group Inc. boosted its holdings in ChromaDex by 870.6% during the 2nd quarter. Goldman Sachs Group Inc. now owns 182,633 shares of the company’s stock worth $698,000 after acquiring an additional 163,817 shares during the last quarter. Thompson Davis & CO. Inc. purchased a new position in ChromaDex during the 3rd quarter worth $128,000. Finally, Granite Investment Partners LLC boosted its holdings in ChromaDex by 5.7% during the 3rd quarter. Granite Investment Partners LLC now owns 250,276 shares of the company’s stock worth $1,076,000 after acquiring an additional 13,599 shares during the last quarter. 6.82% of the stock is owned by institutional investors and hedge funds.

WARNING: This piece was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.com-unik.info/2017/12/04/chromadex-cdxc-downgraded-by-valuengine.html.

About ChromaDex

Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.

To view ValuEngine’s full report, visit ValuEngine’s official website.

What are top analysts saying about ChromaDex Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ChromaDex Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit